LB Pharmaceuticals Inc
LBRX
Positions held
Your positionsLBRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- LB Pharmaceuticals Inc. operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company's market cap stands at approximately $1.1 billion, indicating a strong presence in the market.
- Despite current losses, analysts have given a 'strong buy' recommendation with a target mean price of $57.3.
- The company has not generated any revenue in recent quarters, which raises concerns about its financial viability.
- In the most recent quarter, LB Pharmaceuticals reported a net income loss of $51.603 million, continuing a trend of negative earnings.
- The stock has a trailing P/E ratio of 342.6, suggesting that it may be overvalued given its current financial performance.
Fundamentals
| Market cap | $1.12B | Enterprise value | $793.92M | Trailing P/E | 346.10 | Forward P/E | -6.69 |
| PEG | — | Price / book | 2.99 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -50.0% | ROA | -30.0% | Debt / equity | 0.02 |
| Current ratio | 15.08 | Free cash flow | -$53.92M | Analyst recommendation | strong_buy | Mean target | $57.30 |
| 52w high | $50.16 | 52w low | $14.32 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$51.6M | -$19.1M | -$11.5M | -$3.6M | -$4.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$53.9M | -$22.1M | -$13.9M | -$5.2M | -$4.9M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$25.2M | -$63.1M | -$6.3M | -$14.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$30.4M | -$64.8M | -$11.4M | -$2.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Canaccord Genuity Initiates LB Pharmaceuticals at Buy With $65 Price Target
2026-10-06 · Guggenheim Initiates LB Pharmaceuticals at Buy With $80 Price Target
2026-10-05 · Roth Capital Downgrades LB Pharmaceuticals to Neutral From Buy, Price Target is $37
2026-10-02 · Needham Initiates LB Pharmaceuticals at Buy With $68 Price Target
2026-09-15 · LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
2026-09-09 · IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
2026-09-04 · 2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
2026-09-03 · LB Pharmaceuticals to Participate in Upcoming September Investor Events
2026-09-03 · LB Pharmaceuticals Names Joseph Miller CFO
2026-09-03 · LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
2026-08-11 · LB Pharmaceuticals Q2 Loss Per Share Narrows
Price (daily)
Full chart · RSI · MACD · patterns